Saba Capital Management, L.P. Buys 81,738 Shares of Abrdn Life Sciences Investors (NYSE:HQL) Stock

Abrdn Life Sciences Investors (NYSE:HQL) major shareholder Saba Capital Management, L.P. purchased 81,738 shares of the company’s stock in a transaction dated Thursday, April 18th. The shares were acquired at an average price of $12.80 per share, for a total transaction of $1,046,246.40. Following the purchase, the insider now directly owns 2,694,511 shares in the company, valued at $34,489,740.80. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

• On Monday, April 22nd, Saba Capital Management, L.P. bought 2,022 shares of Abrdn Life Sciences Investors stock. The stock was bought at an average cost of $12.88 per share, for a total transaction of $26,043.36.

Abrdn Life Sciences Investors Stock Performance

Shares of HQL opened at $13.15 on Wednesday. The business has a 50-day simple moving average of $13.55 and a two-hundred day simple moving average of $13.10. Abrdn Life Sciences Investors has a 52 week low of $11.34 and a 52 week high of $14.37.

Abrdn Life Sciences Investors Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Thursday, February 22nd were paid a dividend of $0.39 per share. The ex-dividend date of this dividend was Wednesday, February 21st. This is an increase from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.30. This represents a $1.56 dividend on an annualized basis and a dividend yield of 11.86%.

Institutional Investors Weigh In On Abrdn Life Sciences Investors

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC lifted its stake in shares of Abrdn Life Sciences Investors by 12.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 347,615 shares of the company’s stock valued at $4,335,000 after buying an additional 38,000 shares in the last quarter. 180 Wealth Advisors LLC grew its holdings in Abrdn Life Sciences Investors by 5.3% during the 3rd quarter. 180 Wealth Advisors LLC now owns 114,724 shares of the company’s stock valued at $1,431,000 after buying an additional 5,725 shares in the last quarter. Shaker Financial Services LLC raised its position in shares of Abrdn Life Sciences Investors by 2.1% during the third quarter. Shaker Financial Services LLC now owns 66,528 shares of the company’s stock valued at $830,000 after buying an additional 1,342 shares during the last quarter. Private Advisor Group LLC lifted its holdings in shares of Abrdn Life Sciences Investors by 78.9% in the third quarter. Private Advisor Group LLC now owns 35,046 shares of the company’s stock worth $435,000 after buying an additional 15,459 shares in the last quarter. Finally, RPO LLC boosted its position in shares of Abrdn Life Sciences Investors by 75.7% during the third quarter. RPO LLC now owns 327,042 shares of the company’s stock worth $4,078,000 after acquiring an additional 140,942 shares during the last quarter. Institutional investors own 32.21% of the company’s stock.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.